Loading
Veru Inc. Stock: price and insider trades · United States
1 insider bought €4,198 of shares over the last 90 days, the latest by BARNETTE K GARY, filed 17 Aug 2026.
Veru Inc.: what insiders have been doing
Veru Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 1 filing came from 1 insider.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €4,198. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 1 senior executive. Biggest ticket of the year: €4,198, bought by Barnette K Gary and made public on 17 August 2026 (0.011% of market cap).
The latest purchase dates back some time: it was published 68 days ago, on 17 August 2026.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 1 filing, this issuer sits below that mark. The full history, which starts in 2016, counts 98 purchases against 42 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
169
Thresholds
n/a
Buy Volume
€1M
98 ops. · all time
Sell Volume
€7M
42 ops. · all time
Who traded when
BuySaleMichael L. Rankowitz2 buys
K. Gary Barnette1 buy
Since the insiders bought
- -6.6%Entry US$2.59 · Close 16 Oct 2026 US$2.42
- -56.5%Entry US$5.70 · Close at T+365 US$2.48
- -49.0%Entry US$10.00 · Close at T+365 US$5.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Veru Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$25.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended September 2025 · cache
US$2.31
Analyst consensus
3 analystsStrong buy
US$24.00Target US$25.67(+1011%)US$28.00
Income statement
Gross profitUS$5.9M
EBITDA-US$35.4M
Net income-US$22.7M0.0% margin
Valuation
PER (forward)-2.3x
P/Book1.4x
Beta-1.20
Balance sheet & cash
Market capUS$39.4M
Total debtUS$3.1M
Free Cash Flow-US$30M
Debt / Equity9%
Profitability & ownership
ROE-64.5%
ROA-54.0%
% insiders9.2%
% institutions19.0%
Last declaration on 17 August 2026
Declarations169 total
1,800 shares@ US$2.68990.011% mcap40.4% of flowCommon StockSEC:0001042167-26-000060:0
Canonical exit: 11 Nov 2026 (T+90)
54,721 shares@ US$0.583337.9% of flowCommon StockSEC:0001042167-25-000007:1
Canonical exit: 20 May 2025 (T+90)
95,279 shares@ US$0.5503100.0% of flowCommon StockSEC:0001042167-25-000007:0
Canonical exit: 19 May 2025 (T+90)
4,000 shares@ US$1.250.7% of flowCommon StockSEC:0001042167-24-000044:0
Canonical exit: 22 Aug 2024 (T+90)
300 shares@ US$1.350.0% of flowCommon StockSEC:0001042167-24-000042:1
63,379 shares@ US$1.232.1% of flowCommon StockSEC:0001042167-24-000042:2
6,504 shares@ US$1.38666.7% of flowCommon StockSEC:0001042167-24-000042:0
5,000 shares@ US$1.339359.6% of flowCommon StockSEC:0001042167-24-000043:0
Canonical exit: 22 Aug 2024 (T+90)
59,788 shares@ US$1.412.3% of flowCommon StockSEC:0001042167-24-000039:1
28,066 shares@ US$1.321.0% of flowCommon StockSEC:0001042167-24-000039:2
6,711 shares@ US$1.491.3% of flowCommon StockSEC:0001042167-24-000040:0
Canonical exit: 13 Aug 2024 (T+90)
84,021 shares@ US$1.497493.3% of flowCommon StockSEC:0001042167-24-000039:0
5,000 shares@ US$1.500.3% of flowCommon StockSEC:0001042167-22-000038:1
5,000 shares@ US$2.080.5% of flowCommon StockSEC:0001042167-22-000038:2
45,000 shares@ US$1.893.9% of flowCommon StockSEC:0001042167-22-000038:3
100,000 shares@ US$20.0492.7% of flowCommon StockSEC:0001042167-22-000038:4
45,000 shares@ US$1.20100.0% of flowCommon StockSEC:0001042167-22-000038:0
4,800 shares@ US$6.7796100.0% of flowCommon StockSEC:0001042167-21-000061:0
Canonical exit: 15 Nov 2021 (T+90)
100,000 shares@ US$8.35398.1% of flowCommon StockSEC:0001042167-21-000049:0
3,500 shares@ US$14.09100.0% of flowCommon StockSEC:0001042167-21-000030:0
Canonical exit: 8 Jun 2021 (T+90)
20,000 shares@ US$20.8810.7% of flowCommon StockSEC:0001042167-21-000013:0
100,000 shares@ US$10.645198.8% of flowCommon StockSEC:0001042167-20-000066:0
250,000 shares@ US$9.686594.1% of flowCommon StockSEC:0001042167-20-000065:0
5,000 shares@ US$2.761.6% of flowCommon StockSEC:0001042167-20-000031:0
Canonical exit: 24 Nov 2020 (T+90)
5,000 shares@ US$2.65100.0% of flowCommon StockSEC:0001042167-20-000030:0
Canonical exit: 22 Nov 2020 (T+90)
25 of 169 declarations
About Veru Inc.
Veru Inc. is a U.S.-based biopharmaceutical company listed on NASDAQ in the United States and focused on late-stage clinical development in cardiometabolic and inflammatory diseases. Headquartered in Miami, Florida, Veru has evolved over time from an earlier corporate identity into a specialized life sciences company with a strong emphasis on research and development rather than commercial scale. Its business model is typical of a clinical-stage biotech: high scientific optionality, significant regulatory dependence, and ongoing reliance on capital markets to fund development programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000863894/000143774925038089/veru20250930_10k.htm?utm_source=openai))
The company’s recent strategic focus has centered on obesity and the preservation of lean muscle mass. Veru’s lead asset is enobosarm, an oral selective androgen receptor modulator (SARM) being studied in combination with GLP-1 receptor agonists such as semaglutide. The goal is to improve the “quality” of weight loss by reducing fat mass while preserving lean mass, physical function, and bone health. In 2025 and 2026, Veru disclosed meaningful progress on this program, including a favorable FDA meeting that provided regulatory clarity for its obesity development path and the initiation of the Phase 2b PLATEAU trial. Management has said an interim analysis is expected in the first quarter of calendar 2027. ([ir.verupharma.com](https://ir.verupharma.com/news-events/press-releases/detail/242/veru-announces-successful-fda-meeting-providing-regulatory?utm_source=openai))
Read moreShow less
Veru describes itself in recent communications as a late clinical-stage biopharmaceutical company focused on innovative medicines for cardiometabolic and inflammatory diseases. That positioning places the company in a targeted niche rather than in direct competition with large pharmaceutical companies across a broad therapeutic portfolio. From a competitive standpoint, Veru remains a small-cap, high-risk equity whose valuation is heavily driven by clinical readouts, FDA interactions, and financing capacity. The company has also noted an effective $200 million shelf registration capacity, underscoring that access to capital remains central to executing its pipeline strategy. ([ir.verupharma.com](https://ir.verupharma.com/news-events/press-releases/detail/254/veru-reports-fiscal-2026-second-quarter-financial-results?utm_source=openai))
Historically, Veru previously worked across several therapeutic areas, including urology, oncology, and antiviral programs, before narrowing its focus toward higher-value cardiometabolic opportunities. That portfolio evolution is important for investors because it reflects a classic biotech strategy: concentrate resources on the asset with the clearest scientific and commercial potential while de-emphasizing legacy programs. For French-speaking investors in France, Belgium, and Switzerland, Veru should therefore be viewed as a science-driven, event-driven NASDAQ company in the United States, with upside tied to clinical execution and regulatory progress rather than established recurring revenues. ([verupharma.com](https://verupharma.com/?utm_source=openai))
